Tabriziani Hossein, Ahmad Armaghan, Narasimha Deepika, Bergamaschi Roberto, Frishman William H
Cardiol Rev. 2018 Mar/Apr;26(2):99-106. doi: 10.1097/CRD.0000000000000180.
Mesenteric ischemia is a rare disorder, with considerably high morbidity and mortality rates. It can manifest in several ways, including acute mesenteric ischemia, chronic mesenteric ischemia, nonocclusive mesenteric ischemia, mesenteric venous thrombosis, and colonic ischemia. Of these, acute mesenteric ischemia is the most severe form of intestinal ischemia, with a high mortality rate. The mainstay of therapy for mesenteric ischemia is surgical exploration and resection of infarcted bowel; however, medical therapy can play an important adjunctive role. When diagnosed early, before bowel infarction, endovascular therapy can be used as the primary treatment option. Endovascular therapy includes catheter-based thrombolysis, thromboembolectomy, and stenting. Vasodilators also play an important role in the early management of mesenteric ischemia. Anticoagulation is the main form of therapy in mesenteric venous thrombosis.
肠系膜缺血是一种罕见疾病，发病率和死亡率相当高。它可通过多种方式表现出来，包括急性肠系膜缺血、慢性肠系膜缺血、非闭塞性肠系膜缺血、肠系膜静脉血栓形成和结肠缺血。其中，急性肠系膜缺血是肠道缺血最严重的形式，死亡率很高。肠系膜缺血的主要治疗方法是手术探查和切除梗死肠段；然而，药物治疗可发挥重要的辅助作用。在肠梗死之前早期诊断时，血管内治疗可作为主要治疗选择。血管内治疗包括基于导管的溶栓、血栓切除术和支架置入术。血管扩张剂在肠系膜缺血的早期管理中也发挥着重要作用。抗凝是肠系膜静脉血栓形成的主要治疗方式。
